| Identification | Back Directory | [Name]
VCE-004.8 | [CAS]
1818428-24-8 | [Synonyms]
EPH001
EHP-101
VCE-004.8
etrinabdione
EHP-101 (VCE- 004.8)
Peroxisome proliferator-activated receptors,EHP101,HIF-PH,Hypoxia-inducible factors,inhibit,VCE-?004.8,EHP 101,PPAR,Inhibitor,HIF/HIF Prolyl-Hydroxylase,Cannabinoid Receptor,HIFs,EHP-101 | [Molecular Formula]
C28H35NO3 | [MOL File]
1818428-24-8.mol | [Molecular Weight]
433.58 |
| Chemical Properties | Back Directory | [Boiling point ]
588.6±50.0 °C(Predicted) | [density ]
1.12±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 100 mg/mL (230.64 mM) | [form ]
Solid | [pka]
3.44±0.50(Predicted) | [color ]
Pale purple to purple |
| Hazard Information | Back Directory | [Uses]
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2]. | [in vivo]
Etrinabdione (i.p.; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. Etrinabdione can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels[1]. | [IC 50]
PPARγ; CB2 | [storage]
Store at -20°C | [References]
[1] Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15(1):64. DOI:10.1186/s12974-018-1103-y
[2] Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092. DOI:10.1038/s41598-018-34259-0 |
|
|